Moderna (MRNA) President Stephen Hoge Sells $8.4M of Stock

Moderna, Inc. (NasdaqGS: MRNA) President Stephen Hoge unloaded 39,224 shares of the biotechnology company on October 14, 2026. According to a Form 4 filing with the SEC, the stock was sold at an average price of $213.48 per share, for a total value of about $8.37 million.

Inside Stephen Hoge's Trade

The planned sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Hoge's holdings in the Cambridge, Massachusetts-based vaccine and messenger RNA medicine developer adjusted downward. The stock closed at $226.30 on the day of the trade.

Other Institutional Activity in Moderna

Large financial firms have also adjusted their positions in Moderna recently. FMR, LLC grew its holdings by 6,188,477 shares, ending with 51,859,891 shares worth about $11.31 billion. Blackrock Inc. added 963,178 shares to hold 30,599,409 shares valued at roughly $6.67 billion. Vanguard Capital Management LLC boosted its stake by 336,227 shares to own 23,208,792 shares worth approximately $5.06 billion. Capital World Investors lifted its position by 3,578,829 shares to 22,276,996 shares valued at about $4.86 billion. Meanwhile, BAILLIE GIFFORD & CO cut 1,778,708 shares, leaving it with 18,206,778 shares worth roughly $3.97 billion.

Moderna, Inc. Stock Down 3.7%

Moderna shares recently traded around $218.00, sitting roughly 10.0% below their 52-week high of $242.29. The stock has experienced a strong run, trading well above its 200-day moving average of $75.43 and its 50-day moving average of $148.05.

Recent Earnings

Moderna reported trailing-twelve-month revenue of $2.23 billion with an earnings per share loss of $7.98. The company's net profit margin stood at -141.4% with a return on equity of -39.0%. Moderna is scheduled to release its next financial results on November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Insiders have been active with their shares over recent months. Chief Executive Officer Stephane J Bancel disposed of 499,246 shares on August 5, 2026, for about $28.72 million. Officer Shannon Thyme Klinger sold 3,471 shares on September 1, 2026, at $139.95 apiece, totaling $485,766. Chief Financial Officer James M Mock parted with 34,836 shares on September 10, 2026, at $134.49 per share for a total of $4.69 million. Stephen Hoge previously sold 80,575 shares on September 15, 2026, valued at $11.69 million.

Analysts Set New Price Targets

Wall Street firms continue to update their views on the stock. Wolfe Research upgraded the shares to a Peer Perform rating on August 25, 2026. Argus Research lifted its rating to Buy with an $180.00 price target on August 28, 2026. Rothschild & Co lowered its rating to Sell, moving its target from $40.00 to $81.00 on September 3, 2026. Citigroup cut its rating to Sell and set an $80.00 price target on September 30, 2026. Morgan Stanley maintained an Equal-Weight rating while raising its target from $89.00 to $95.00 on October 7, 2026. Overall, the stock carries a consensus hold rating and an average price target of $123.61 across 18 analyst opinions.

About Moderna

Moderna, Inc. focuses on discovering and developing messenger RNA therapeutics and vaccines to treat various infectious diseases, immuno-oncology conditions, and rare diseases. The company uses its proprietary technology platform to direct the body's cellular machinery to produce targeted proteins.

Bottom Line

Stephen Hoge's sale highlights ongoing insider transactions as the stock trades well above its long-term moving averages. Investors will look toward the upcoming earnings report on November 6, 2026, for further updates on revenue and product pipelines.